Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for ...

An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year ...

Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the ...

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Consistent Dividend Stocks to Buy Right Now. On April 6, JPMorgan ...

Shares of Apple and Merck are trading lower Tuesday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of Apple and Merck have contributed to the index's intraday ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising ...

March 30 () - Merck's oral drug reduced bad cholesterol by up to ‌64.6% in a late-stage trial, ‌the drugmaker said on Monday, ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully ...

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...